ES2191611T3 - Compuesto bajo forma de isomero geometrico u optico puro o de mezcla de tales isomeros. - Google Patents
Compuesto bajo forma de isomero geometrico u optico puro o de mezcla de tales isomeros.Info
- Publication number
- ES2191611T3 ES2191611T3 ES00907746T ES00907746T ES2191611T3 ES 2191611 T3 ES2191611 T3 ES 2191611T3 ES 00907746 T ES00907746 T ES 00907746T ES 00907746 T ES00907746 T ES 00907746T ES 2191611 T3 ES2191611 T3 ES 2191611T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl group
- phenyl
- group
- alkyl
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000003287 optical effect Effects 0.000 title abstract 2
- 239000002131 composite material Substances 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 5
- -1 phenyl hydroxy Chemical group 0.000 abstract 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Compuesto bajo forma de isomero geométrico u óptico puro o de mezcla de tales isomeros, de fórmula general (I), **(Fórmula)** en la que R1 representa un átomo de hidrógeno, un grupo (C1-C4)alquilo, un grupo fenil(C1-C4)alquilo, un grupo fenil hidroxi(C1-C4)alquilo, un grupo furanil(C1-C4)alquilo o un grupo furanil hidroxi(C1-C4)alquilo, R2 representa o bien un átomo de hidrógeno o de halógeno o un grupo trifluorometilo, ciano, hidroxi, nitro, acetilo, (C1-C6)alquilo, (C1-C6)alcoxi o un grupo de fórmula general NR4R5 en la que R4 representa un átomo de hidrógeno o un grupo (C1-C4)alquilo o (C1-C4)alcanoilo y R5 representa un átomo de hidrógeno o un grupo (C1-C4)alquilo, o bien R4 y R5 forman, con el átomo de nitrógeno que los lleva, un ciclo de C4-C7, ya sea un grupo fenilo o naftilo eventualmente sustituido por un átomo de halógeno o un grupo trifluorometilo, trifluorometoxi, ciano, hidroxi, nitro, acetilo, (C1-C6)alquilo, (C1-C6, )alcoxi, metilenedioxi unido a las posiciones 2 y 3 o 3 y 4del ciclo fenilo, o fenilo, y R3 representa un átomo de hidrógeno o de halógeno o un grupo (C1-C4) alquilo en estado de base o de sal de adición con un ácido.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9902784A FR2790474B1 (fr) | 1999-03-05 | 1999-03-05 | Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2191611T3 true ES2191611T3 (es) | 2003-09-16 |
Family
ID=9542888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES00907746T Expired - Lifetime ES2191611T3 (es) | 1999-03-05 | 2000-03-01 | Compuesto bajo forma de isomero geometrico u optico puro o de mezcla de tales isomeros. |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US6538003B1 (es) |
| EP (1) | EP1161434B1 (es) |
| JP (1) | JP4806123B2 (es) |
| KR (2) | KR100768355B1 (es) |
| CN (1) | CN1137894C (es) |
| AR (1) | AR022820A1 (es) |
| AT (1) | ATE231869T1 (es) |
| AU (1) | AU764625B2 (es) |
| BG (1) | BG65211B1 (es) |
| BR (1) | BR0008763A (es) |
| CA (1) | CA2372063C (es) |
| CO (1) | CO5160250A1 (es) |
| CZ (1) | CZ302259B6 (es) |
| DE (1) | DE60001307T2 (es) |
| DK (1) | DK1161434T3 (es) |
| EE (1) | EE04497B1 (es) |
| ES (1) | ES2191611T3 (es) |
| FR (1) | FR2790474B1 (es) |
| HK (1) | HK1040398B (es) |
| HR (1) | HRP20010655B1 (es) |
| HU (1) | HU228671B1 (es) |
| ID (1) | ID30116A (es) |
| IL (2) | IL145150A0 (es) |
| MX (1) | MXPA01008972A (es) |
| NO (1) | NO327119B1 (es) |
| NZ (1) | NZ513561A (es) |
| PE (1) | PE20001543A1 (es) |
| PL (1) | PL201683B1 (es) |
| RS (1) | RS49997B (es) |
| RU (1) | RU2238273C2 (es) |
| SK (1) | SK284339B6 (es) |
| TR (1) | TR200102403T2 (es) |
| TW (1) | TWI222975B (es) |
| UA (1) | UA61164C2 (es) |
| UY (1) | UY26048A1 (es) |
| WO (1) | WO2000053608A1 (es) |
| ZA (1) | ZA200106811B (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| WO2004009116A2 (en) | 2002-07-18 | 2004-01-29 | Cytos Biotechnology Ag | Hapten-carrier conjugates comprising virus like particles and uses thereof |
| US7238715B2 (en) * | 2002-12-06 | 2007-07-03 | The Feinstein Institute For Medical Research | Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists |
| DE60317564T2 (de) * | 2002-12-06 | 2008-10-23 | The Feinstein Institute For Medical Research | Hemmung von entzündungen unter verwendung von alpha-7-rezeptor verbindenden cholinergen agonisten |
| US8580842B2 (en) | 2003-09-30 | 2013-11-12 | Abbott Gmbh & Co. Kg | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them |
| US8316104B2 (en) | 2005-11-15 | 2012-11-20 | California Institute Of Technology | Method and apparatus for collaborative system |
| US20080167286A1 (en) | 2006-12-12 | 2008-07-10 | Abbott Laboratories | Pharmaceutical compositions and their methods of use |
| US8486979B2 (en) * | 2006-12-12 | 2013-07-16 | Abbvie Inc. | 1,2,4 oxadiazole compounds and methods of use thereof |
| UY30846A1 (es) * | 2006-12-30 | 2008-07-31 | Abbott Gmbh & Amp | Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos |
| US20080255203A1 (en) * | 2007-04-12 | 2008-10-16 | Abbott Laboratories | Heterocyclic compounds and their methods of use |
| US20090076059A1 (en) * | 2007-09-19 | 2009-03-19 | Protia, Llc | Deuterium-enriched dianicline |
| WO2010009775A1 (de) | 2007-12-07 | 2010-01-28 | Abbott Gmbh & Co. Kg | Carbamat-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen |
| ES2397125T3 (es) * | 2007-12-07 | 2013-03-04 | Abbott Gmbh & Co. Kg | Derivados de oxindol sustituidos con halógeno en la posición 5 y su uso para la producción de un medicamento para el tratamiento de enfermedades dependientes de la vasopresina |
| MX2010006204A (es) | 2007-12-07 | 2011-03-16 | Abbott Gmbh & Co Kg | Derivados de oxindol 5,6-disubstituidos y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina. |
| CN101981027B (zh) | 2007-12-07 | 2014-08-06 | Abbvie德国有限责任两合公司 | 氨基甲基取代的羟吲哚衍生物及其用于治疗加压素依赖性疾病的用途 |
| US20090221648A1 (en) * | 2007-12-21 | 2009-09-03 | Abbott Laboratories | Compositions for treatment of cognitive disorders |
| US8383657B2 (en) * | 2007-12-21 | 2013-02-26 | Abbott Laboratories | Thiazolylidine urea and amide derivatives and methods of use thereof |
| WO2009146031A1 (en) | 2008-03-31 | 2009-12-03 | University Of South Florida | Methods of treating disease-induced ataxia and non-ataxic imbalance |
| PL2540297T3 (pl) | 2008-11-19 | 2015-12-31 | Forum Pharmaceuticals Inc | Leczenie zaburzeń funkcji poznawczych(R)-7-chloro-N-(chinuklidyn-3-ylo)benzo[b]tiofeno-2-karboksyamidem i jego farmaceutyczne dopuszczalnymi solami |
| TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
| CN102802620A (zh) * | 2009-05-11 | 2012-11-28 | 英维沃医药有限公司 | 使用某种α-7烟酸受体与乙酰胆碱酯酶抑制剂结合治疗认知障碍 |
| WO2010138600A2 (en) * | 2009-05-29 | 2010-12-02 | Abbott Laboratories | Pharmaceutical compositions for the treatment of pain |
| KR101698250B1 (ko) | 2010-05-17 | 2017-01-19 | 포럼 파마슈티칼즈 인크. | (R)-7-클로로-N-(퀴누클리딘-3-일)벤조[b]티오펜-2-카르복사미드 히드로클로리드 모노히드레이트의 결정질 형태 |
| RU2635522C2 (ru) | 2012-05-08 | 2017-11-13 | Форум Фармасьютикалз, Инк. | Способы поддержания, лечения или улучшения когнитивной функции |
| US9585867B2 (en) | 2015-08-06 | 2017-03-07 | Charles Everett Ankner | Cannabinod formulation for the sedation of a human or animal |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3008226B2 (ja) * | 1991-01-16 | 2000-02-14 | 第一製薬株式会社 | 六環性化合物 |
| GB9301660D0 (en) * | 1993-01-28 | 1993-03-17 | Smithkline Beecham Plc | Pharmaceuticals |
| JPH11512443A (ja) * | 1995-09-22 | 1999-10-26 | ノボ ノルディスク アクティーゼルスカブ | 新規な置換アザ環式またはアザ二環式化合物 |
| FR2761072B1 (fr) * | 1997-03-20 | 1999-04-23 | Synthelabo | Derives de 2,3-dihydrofuro[3,2-b]pyridine, leur preparation et leur application en therapeutique |
| ATE254618T1 (de) * | 1997-05-30 | 2003-12-15 | Neurosearch As | Spiro chinuclidin-derivate, ihre herstellung und verwendung |
| AR013184A1 (es) * | 1997-07-18 | 2000-12-13 | Astrazeneca Ab | Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis |
| SE9900100D0 (sv) * | 1999-01-15 | 1999-01-15 | Astra Ab | New compounds |
-
1999
- 1999-03-05 FR FR9902784A patent/FR2790474B1/fr not_active Expired - Fee Related
-
2000
- 2000-01-03 UA UA2001085808A patent/UA61164C2/uk unknown
- 2000-03-01 HU HU0201753A patent/HU228671B1/hu not_active IP Right Cessation
- 2000-03-01 CA CA2372063A patent/CA2372063C/en not_active Expired - Fee Related
- 2000-03-01 ES ES00907746T patent/ES2191611T3/es not_active Expired - Lifetime
- 2000-03-01 US US09/913,679 patent/US6538003B1/en not_active Expired - Lifetime
- 2000-03-01 CN CNB008046662A patent/CN1137894C/zh not_active Expired - Fee Related
- 2000-03-01 ID IDW00200101796A patent/ID30116A/id unknown
- 2000-03-01 DE DE60001307T patent/DE60001307T2/de not_active Expired - Lifetime
- 2000-03-01 MX MXPA01008972A patent/MXPA01008972A/es unknown
- 2000-03-01 NZ NZ513561A patent/NZ513561A/xx not_active IP Right Cessation
- 2000-03-01 HK HK02101759.7A patent/HK1040398B/zh not_active IP Right Cessation
- 2000-03-01 EE EEP200100470A patent/EE04497B1/xx not_active IP Right Cessation
- 2000-03-01 RS YUP-596/01A patent/RS49997B/sr unknown
- 2000-03-01 CZ CZ20013102A patent/CZ302259B6/cs not_active IP Right Cessation
- 2000-03-01 AT AT00907746T patent/ATE231869T1/de active
- 2000-03-01 JP JP2000604044A patent/JP4806123B2/ja not_active Expired - Fee Related
- 2000-03-01 TR TR2001/02403T patent/TR200102403T2/xx unknown
- 2000-03-01 KR KR1020017011245A patent/KR100768355B1/ko not_active Expired - Fee Related
- 2000-03-01 HR HR960321A patent/HRP20010655B1/xx not_active IP Right Cessation
- 2000-03-01 PL PL352330A patent/PL201683B1/pl unknown
- 2000-03-01 EP EP00907746A patent/EP1161434B1/fr not_active Expired - Lifetime
- 2000-03-01 IL IL14515000A patent/IL145150A0/xx active IP Right Grant
- 2000-03-01 CO CO00014724A patent/CO5160250A1/es unknown
- 2000-03-01 RU RU2001123126/04A patent/RU2238273C2/ru not_active IP Right Cessation
- 2000-03-01 AU AU29226/00A patent/AU764625B2/en not_active Ceased
- 2000-03-01 SK SK1242-2001A patent/SK284339B6/sk not_active IP Right Cessation
- 2000-03-01 WO PCT/FR2000/000502 patent/WO2000053608A1/fr not_active Ceased
- 2000-03-01 KR KR1020077013746A patent/KR20070086359A/ko not_active Withdrawn
- 2000-03-01 DK DK00907746T patent/DK1161434T3/da active
- 2000-03-01 BR BR0008763-7A patent/BR0008763A/pt not_active Application Discontinuation
- 2000-03-03 AR ARP000100942A patent/AR022820A1/es active IP Right Grant
- 2000-03-03 PE PE2000000187A patent/PE20001543A1/es not_active Application Discontinuation
- 2000-03-03 UY UY26048A patent/UY26048A1/es not_active IP Right Cessation
- 2000-03-08 TW TW089103753A patent/TWI222975B/zh not_active IP Right Cessation
-
2001
- 2001-08-16 BG BG105828A patent/BG65211B1/bg unknown
- 2001-08-17 ZA ZA200106811A patent/ZA200106811B/en unknown
- 2001-08-28 IL IL145150A patent/IL145150A/en not_active IP Right Cessation
- 2001-09-03 NO NO20014270A patent/NO327119B1/no not_active IP Right Cessation
-
2003
- 2003-02-06 US US10/359,881 patent/US6908927B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2191611T3 (es) | Compuesto bajo forma de isomero geometrico u optico puro o de mezcla de tales isomeros. | |
| ES2192520T3 (es) | Composicion farmaceutica. | |
| AR000039A2 (es) | Compuestos de piridinosulfonamida sustituidos, composiciones herbicidas que los contienen, metodo para preparar estos compuestos y compuestosintermediarios. | |
| AR043436A1 (es) | Tetrahidroisoquinolinas sustituidas para uso como moduladores 5-ht6 | |
| AR038383A1 (es) | Compuesto inhibidor de la hepatitis c | |
| CO6321266A2 (es) | Inhibidores limk2 compuestos de los cuales estan hechos y metodologia de uso | |
| CO5700820A2 (es) | Derivados de dioxan-2-alquilcarbamatos, su preparacion y su aplicacion en terapeutica | |
| AR041271A1 (es) | Quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesterasa | |
| AR048213A1 (es) | 1-(4-mono-y di-halometilsulfonilfenil)-2-acilamino-fluorpropanoles analogos al florfenicol | |
| ES8600211A1 (es) | Un procedimiento para la preparacion de nuevos derivados arilfenilicos | |
| AR044883A1 (es) | Derivados del 8-aza-biciclo [3.2.1] octano y su uso como inhibidores de la recaptacion de neurotransmisores monoaminicos | |
| SV2002000244A (es) | Metodos y compuestos para inhibir mrp1 ref.x-13353 | |
| ES2137512T3 (es) | Derivados de amidina biciclicos como inhibidores de la sintetasa de oxido nitrico. | |
| CO4940417A1 (es) | DERIVADOS DE 2,3-DIHIDROFURO[3,2-b]PIRIDINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICA | |
| BR0114753A (pt) | Processo para a preparação de compostos de bis-benzazolila | |
| CO4750656A1 (es) | Derivados de 5-aril-3-(8-azabiciclo[3.2.1]oct-3-il)-1,3,4- oxadiazol-2 (3h)-ona, su preparacion y medicamentos que lo contienen | |
| CO4890850A1 (es) | Derivados de 6-pirrolidin-2-ilpiridinas, su reparacion y preparacion en terapeutica. | |
| ES2038656T3 (es) | Derivados de la tiometilpenicilina substituidos en beta y su preparacion y uso. | |
| CO5080758A1 (es) | DERIVADOS DE 3-(2-oxo-[1,3´]BIPIRROLODINIL-3-ILIDENMETIL | |
| AR050032A1 (es) | Derivados de acido benzoico como inhibidores no nucleosidos de la transcriptasa inversa | |
| MX174374B (es) | Compuestos hidrosolubles de acido monoazo-naftencarboxilico procedimiento para su preparacion y su empleo como colorantes | |
| CO5040081A1 (es) | Nuevos compuestos vidad farmaaceutica | |
| ES2167902T3 (es) | Mezclas fungicidas. | |
| ES2036528T3 (es) | Procedimiento para la obtencion de derivados aromaticos. | |
| SE8103940L (sv) | 6-hydrazono-pyrido(2,1)kinazolin-11-oner jemte sett for deras framstellning |